Nordhealth AS

As of June 30, 2026, Nordhealth AS carries a market capitalization of 176.54M, placing it among publicly traded companies globally. Its enterprise value stands at 164.04M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Nordhealth AS's next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Nordhealth AS has 78.81M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.32, and the price-to-book ratio stands at 3.21.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.09 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 164.04M versus a market cap of 176.54M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Nordhealth AS maintains a current ratio of 1.60, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Nordhealth AS posted a negative return on equity (ROE) of -25.83, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -21.26, reflecting losses generated across the asset base. The company generates approximately 117,899.06 in revenue per employee across its workforce of 450.75, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Nordhealth AS recorded 565,000.00 in income tax expense. The company reported a pretax loss of -15.34M and -15.91M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Nordhealth AS's stock has declined approximately 14.97% over the past 52 weeks. The 50-day moving average sits at 2.31, while the 200-day moving average is 2.38.

Over the twelve months ended June 30, 2026, Nordhealth AS generated 53.14M in revenue and converted that into -15.91M in net income, yielding earnings per share of -0.20. EBITDA reached -3.38M, while operating income came in at -15.12M.

These figures are as of June 30, 2026. Total book value stands at 55.04M, with working capital of 8.16M providing operational flexibility.

Nordhealth AS produced -2.40M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.90M in capital expenditures, free cash flow totaled -7.30M - equivalent to -0.09 per share.

Over the twelve months ended June 30, 2026, Nordhealth AS posted a gross margin of 78.34, reflecting its pricing power and cost economics. The operating margin of -28.45 and net profit margin of -29.94 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -4.14: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

As of June 30, 2026, Nordhealth AS has an Altman Z-Score of 4.68, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.